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Introduction: Papillary thyroid cancer (PTC) is the most common endocrine malignancy.
More than 98% of patients achieve an excellent response with no evidence of clinical,
biochemical, or structural disease after initial treatment. In these patients structural
recurrence is rare, more frequently diagnosed in the first 5 years from initial treatment
and almost invariably localized in neck lymph nodes.
Patient: We report the case of a woman affected by PTC who presented with rapidly
rising anti-thyroglobulin antibodies (TgAb) level after 10 years from clinical, morphological
and biochemical remission.
Diagnosis and Treatment: In 2003, a 56 year old patient was treated with total
thyroidectomy and radioiodine remnant ablation (RRA) for a PTC (2 cm) with minimal
extrathyroidal extension (T3N1aM0 according to the 6th AJCC TNM staging system)
associated with diffuse lymphocytic thyroiditis. In 2004 the patient was free of disease
defined as undetectable Tg after recombinant human TSH administration in the absence
of TgAb and structural disease. Since February 2012 the appearance and progressive
increase of TgAb titer was observed and in 2014 a 18FDG-PET scan documented
three hypermetabolic lesions suggestive of lung micrometastases. The lung lesions
were cytologically confirmed as PTC metastases. Both the primary tissue and the
lung metastasis were positive for BRAF V600E mutation. The patient was treated with
131-radioiodine that showed radioiodine avid lung lesions that lose the ability to take up
iodine at the following treatment. The patient is still alive and the lung lesions are growing
slowly.
Conclusions: Structural recurrence in patients that demonstrated an excellent response
after initial treatment for PTC is extremely rare, and distant metastases exceptional but
possible. This case is peculiar because recurrence was early identified after 10 years
from initial treatment for the presence of detectable TgAb in a patient that had an
histological diagnosis of lymphocytic thyroiditis but with an atypical clinical presentation
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(normal thyroid at neck ultrasound and undetectable TgAb and anti-thyroid peroxidase
antibodies). For this reason TgAb should be tested with Tg in patients with a history of
lymphocytic thyroiditis, either histological or humoral, also when TgAb is in the normal
range and not suggestive of autoimmune thyroiditis.
Keywords: thyroid cancer (TC), TgAb, recurrence, BRAF mutation, lymphocytic thyroiditis
BACKGROUND
Thyroid carcinoma (TC) is the most common endocrine
malignancy accounting for about 4% of all human tumors (1).
The most frequent histotype is PTC accounting for 85–90% of
all TC, followed by follicular thyroid cancer (FTC), medullary
thyroid cancer (MTC), poorly differentiated thyroid cancer
(PDTC), and anaplastic thyroid cancer (ATC) representing 5–10,
3–5, 2–3, and 1% of all TC, respectively (2). Well-differentiated
thyroid carcinoma (DTC), both PTC and FTC, originate from
follicular cells and maintain the ability to concentrate iodine and
producing Tg. These features of differentiation have important
clinical and prognostic implications. In fact, the slow growth
rate of differentiated PTC and the possibility to treat it with
radioactive iodinemake it one of themost curable human cancers
(3). Despite an overall survival of 98.1% after 5 years from
diagnosis PTC recurrence rate is rather high reaching in some
series 30% (4, 5). In the vast majority of cases, structural recurrent
disease is represented by neck lymph nodes and can be suspected
on the basis of detectable levels of serum Tg and easily diagnosed
with neck ultrasound followed by fine needle aspiration biopsy.
Although more frequent in the first 5 years after initial treatment,
recurrent disease could manifest also after 10–20 years (4).
Although Tg is a quite well-recognized and reliable
tumor marker, in subjects with detectable/high titer of
anti-thyroglobulin antibodies (TgAb), that can interfere in
its measurement, Tg is no longer trustable as tumoral marker
(6, 7). In these cases TgAb titer can be used as a surrogate marker
since its disappearance is correlated with the clinical remission
of the disease while its persistence or increase can suggest the
persistence or recurrence of the disease (8–10). In fact, after the
initial treatment (i.e., total thyroidectomy and RRA) thyroid
autoantibodies, specifically TgAb, decrease over the following
years disappearing in a mean of 3 years when the disease is cured
(11). At variance, the persistence or increase of TgAb titer should
induce the suspicious of a persistent or recurrent disease and
further diagnostic tests should be performed (12). On this regard,
several studies have shown that changes in the TgAb levels
can predict the risk of persistence/recurrence in TgAb-positive
PTC patients while patients who obtain undetectable TgAb titer
have an excellent prognosis (13). More recently, the evidence
that an increase in TgAb titer should not be undervalued was
described also in subjects that were not treated with radioiodine
and could indicate the presence of either normal or tumoral
thyroid tissue (14). However, while the previous reported series
were focused on patients with PTC and positive TgAb from the
beginning, the present case is peculiar because the recurrence
was discovered for the appearance, followed by a progressive
increase, of TgAb titer that was negative at the time of PTC
diagnosis. To our knowledge no similar cases have been reported
so far.
CASE PRESENTATION
On January 2003 a 56-year-old woman underwent total
thyroidectomy for a multinodular goiter with a thyroid nodule
that was suspicious for malignancy at cytology. No evidences of
biochemical and/or ultrasonographic features of autoimmune
thyroiditis were present before surgery (15). The histological
diagnosis was papillary thyroid carcinoma (PTC), classical
variant (Figure 1A1) but with focal areas of tall cells, perithyroid
soft tissue invasion, and multifocality. Histology showed also the
presence of a diffuse lymphocytic infiltration (Figure 1A2).A few
central compartment lymph node metastases were also present
(Figure 1A3) (pT3mN1aMx according to the 6th AJCC-TNM
staging system) (16).
On May 2003 the patient was referred to the Endocrine
Oncology Unit of the Department of Clinical and Experimental
Medicine of the University Hospital of Pisa to perform
radioiodine remnant ablation (RRA) with 30 mCi of 131-I, after
levothyroxine (L-T4) withdrawal. Post-therapeutic whole body
scan (pWBS) showed an exclusive uptake in the central neck
that was suggestive for thyroid remnant, serum thyroglobulin
(Tg) was 1.2 ng/ml with undetectable levels of TgAb. On
May 2004 the patient had undetectable Tg (i.e., <0.5 ng/ml)
serum (Immulite 2000 Thyroglobulin; DPC, Los Angeles,
CA) after the administration of recombinant human thyroid
stimulating hormone (rhTSH; Thyrogen; Sanofi Genzyme,
Cambridge, Massachusetts), negative TgAb (AIA-Pack 2000,
Tosoh Corporation, Tokyo, Japan) and negative neck ultrasound
(US). Considering the excellent response to the initial treatment
the patient, accordingly to the American Thyroid Association
guidelines (17), was considered in clinical remission and then
followed with clinical and biochemical (i.e., Tg and TgAb)
controls and neck US every 12–24 months. The clinical
evaluations, neck US and both Tg and TgAbwere negative and/or
undetectable for the following 5 years.
In 2012 an unexpected positive serum TgAb titer was
noted still in the absence of detectable serum Tg. A small
(8mm) indeterminate lymph node was newly detected at neck
US. The titer of TgAb slightly increased over the years and
for this reason on August 2015 the patient was subjected
to a computerized tomography (CT) scan that showed three
small lesions (maximum diameter 12mm) in the lung. A
18Fluorodeoxyglucose-Positron Emission Tomography (18FDG-
PET) scan confirmed the presence of these lesions that were
hypermetabolic (Figure 2A). On November 2015 the largest
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FIGURE 1 | (A) Histological slides of primary PTC and lymph node metastasis. (A1) Primary PTC with well-formed papillary structures (20X, hematoxilyn/eosin); (A2)
collateral diffuse lymphocytic thyroiditis with lymphoid follicles and germinal centers(5X, hematoxilyn/eosin); (A3) lymph node metastatic lesion of PTC (2.5X,
hematoxilyn/eosin). (B) Fine-needle aspiration cytological smears of lung metastastic lesion. (B1) low power magnification showing papillary-like structures with
smooth contours and palisading of nuclei (10X, papanicolau stain); (B2) high power magnification showing nuclear characteristics of PTC (finely granular chromatin
and one pseudoinclusion) (40X, papanicolau stain); (B3) immunocytochemistry showing cytoplasmatic positivity for thyroglobulin, confirming the thyroid origin of the
lung lesion (40X).
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FIGURE 2 | (A) 18FDG-PET scan showing three hypermetabolic nodular lung lesions localized at the medial (1) (SUV max 3.1) and lateral (2) (SUV max 2.7) segment
of the right medium lobe and at the apical segment (3) of the left inferior (SUV max 3.9) lobe of the lungs. (B) pWBS showing 131-I uptake corresponding to the
hypermetabolic lung lesions localized at the medial segment of the right lobe and at the left inferior lobe.
lung nodule, that was located in the inferior left lobe, was
subjected to fine needle biopsy and cytology confirmed that cell
morphology was suggestive of PTC (Figures 1B1,2). Moreover,
the immunohistochemistry was positive for TTF-1 and focally for
Tg (Figure 1B3) and the measurement of Tg in the wash out of
the needle used for the lung cytology was 1780 ng/ml, confirming
the thyroid origin of the lesion. On December 2015 the serum
Tg became slightly detectable and the patient was treated with
150 mCi of 131-I. The pWBS showed two areas of uptake in
the lung that were suggestive of iodine avid lung metastases and
likely corresponding to two of the lesions found at the CT and
PET scan (Figure 2B).On May 2016 serum biomarkers, namely
TgAb, continued to increase and the patient was subjected to a CT
scan that showed a slight increase of the lung lesions (maximum
diameter 14mm). Taking into account the slow but continue
increase of serum biomarkers on December 2016 the patient
was treated with additional 150 mCi of 131-I. At that time the
pWBS didn’t show any radioiodine uptake. On February 2018
the CT scan showed a further increase in one lung lesion that
reached a maximum diameter of 22mm. A detailed history of
TABLE 1 | Patient’s serum Tg values and TgAb titer between 2004 and 2018.
Date Tg (ng/mL) TgAb (IU/mL)
2004–2011 0 0
Feb-2012* 0 5.7
Nov-2014 0 49
Dec-2015 2.31 154
May-2016 0.18 587
Nov-2016 1.15 568
Oct-2017 0 1,369
Feb-2018 0 2,000
*Since 2012 Tg measurement was performed with an ultrasensitive method (Beckman
Coulter, Inc., Fullerton CA) with a functional sensitivity of 0.1 ng/mL while TgAb assay
used was the same during all the follow-up period.
serum biomarkers (i.e., Tg and TgAb) variation is summarized
and shown in Table 1 and Figure 3.
Paraffin embedded slices of the primary tumor tissue and
cytological smears of the metastatic lung lesion were used for
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FIGURE 3 | Graphic representation of the patient’s serum Tg values and TgAb titer between 2004 and 2018.
the DNA extraction that was targeted sequenced with a next
generation sequencing system (Ion S5 deep sequencer, Ion
Torrent, Applied Biosystem) by using a custom panel designed
to analyze all thyroid related oncogene mutations. The analysis
showed the presence of BRAF V600E mutation with an allelic
frequency of 18 and 27% in the lung and primary tumor
tissue, respectively. No other alterations were found with this
analysis.
According to the Hospital rules, the patient signed an
informed consent for the use of her clinical data and biological
specimens for research purposes and publication of this case
report; the study was approved by the Internal Review Board.
DISCUSSION
Papillary thyroid carcinoma is a lymphotropic tumor, especially
in young patients, which shows a high lymphatic spread at
diagnosis while distant metastases are quite rare and account for
<5% of all TC patients, including other histotype (5). The most
frequent sites of PTC metastatization, excluding lymph nodes
and in order of frequency, are lungs, bone, and liver. Although
the presence of a persistent disease after initial treatment, either
biochemical and/or structural, has been reported up to 20–30%
in different series of DTC, structural recurrent disease (i.e., the
reappearance of disease after a period of documented cure) is
not so frequent and it is present in about 1–2% of cases (18, 19).
Disease recurrence rate depends mainly on tumor histology,
gender, patient’s age, and stage of the disease at diagnosis. This
risk is very well-predicted by the risk of recurrence categories
(i.e., low, intermediate and high) described in the American
Thyroid Association guidelines (17). The periodical monitoring
of serum Tg allows to perform an early diagnosis and the
cure of these rare cases. Although the first 5–10 years after the
initial treatment are those with the highest rate of recurrence,
a lifelong follow-up is suggested because of the late onset
recurrences (4).
In about 20–25% of PTC an autoimmune thyroiditis with
circulating TgAb and/or TPOAb, is associated to the tumor
(20). In these cases, the follow-up requires the concurrent
measurement of Tg and TgAb because of the interference of the
latter on the Tg assays and inmany cases TgAb acquire the role of
“Tg surrogate” marker (21, 22). However, although cases of PTC
with a lymphocytic infiltration in the absence of concomitant
serum autoimmunity are also described (21), no studies on the
need to measure TgAb also during the follow-up of these patients
have been reported so far and our case, although peculiar, testifies
this need.
About 60% of PTC are positive for BRAFV600Emutation and
its prognostic role for recurrence and/or mortality is still under
debate (19, 23–26). Nevertheless, there are evidences that BRAF
V600E positive cases have a lower degree of differentiation and,
as a consequence, a lower ability to take up iodine (23, 27, 28).
It is worth to note that this case was harboring a BRAF V600E
mutation with a rather high allelic prevalence both in the primary
and in the lung metastases. This finding can at least partially
support the hypothesis that this mutation could be the driver
of the recurrence and the cause of low uptake and response to
radioiodine (19).
In conclusion, the description of this case is relevant not
only because the recurrence with distant metastases in a
PTC patient who achieved excellent response is exceptional
but also because the way in which recurrent disease was
diagnosed is unusual. In particular, this case underlines the
importance to always measure serum TgAb along with Tg in
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TC patients not only for the interference that the antibodies
can determine on Tg measurement but also for their role as Tg
surrogate marker. The case demonstrates that this is particularly
relevant when histological lymphocytic infiltration is present
even if serum TgAb are negative. In fact the appearance of
the positivity of TgAb allowed the early diagnosis of disease
recurrence and the appropriate treatment and follow-up the
patient.
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